Diagenode Diagnostics logo

Severe Acute Respiratory Syndrome Coronavirus 2

R-DiaSARS-CoV-2™

DDGR-88-L100

Probes & Primers
H2O
Positive control
Negative control

100 TESTS
Internal control suggested

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the name given to the 2019 emerging coronavirus strain. COVID-19 is the name given to the disease associated with the virus. SARS-CoV-2 is a new strain of coronavirus that has not been previously identified in humans.

There is not enough epidemiological information at this time to determine how easily and sustainably this virus spreads between people, but it is currently estimated that, on average, one infected person will infect between two and three more. The virus seems to be transmitted mainly via respiratory droplets that people sneeze, cough, or exhale. The virus can also survive for several hours on surfaces such as tables and door handles.

 The incubation period for COVID-19 is currently estimated at between two and 14 days. At this stage, we know that the virus can be transmitted when people who are infected show flu-like symptoms such as dry coughing, fever and tiredness. There is evidence suggesting that transmission can occur from an infected person with no symptoms; however, uncertainties remain about the effect of transmission by non-symptomatic persons on the epidemic.

 The virus can cause mild, flu-like symptoms such as: fever, cough, difficulty breathing, muscle pain, tiredness. More serious cases develop severe pneumonia, acute respiratory distress syndrome, sepsis and septic shock that can lead to death. Generally elderly people and those with underlying health conditions (e.g. hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer) are considered to be more at risk of developing severe symptoms.

The R-DiaSARS-CoV-2TM kit is an in vitro diagnostic medical device (IVDMD) designed to qualitatively detect by real-time PCR the Severe Acute Respiratory Syndrome Coronavirus 2 in nasopharyngeal swabs collected from patients showing symptoms related to this pathogen.

  • Validation
    DOUBLE-DYE PROBE & PRIMERS
    Targeted pathogens Emission Targeted genes Volume
    SARS-CoV-2 FAM 520 nm E gene 250 µL
    EXTRACTION METHODS
    Sputum Nasopharyngeal
    swabs/washes
    Bronchoalveolar
    Lavage
    geneLEAD VIII
    Magnapure 96 extraction system roche

    Recommended
    Suitable

    PCR instruments
    PSS
    geneLEAD VIII
    Roche
    LightCycler 480
    Bio-Rad
    CFX96

    Recommended
    Suitable

  • Documents

Upcoming events

  • AACC
    Dec 15-Dec 17, 2020
    Chicago, IL, USA
 See all events


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

© 2017 – Diagenode Diagnostics | ISO 13485 | Site Map | Privacy policy | Contact Us | Terms and Conditions |